Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

Stephan Weidinger, Ben Porter‐Brown, Thomas Bieber et al.|British Journal of Dermatology|2023

Cited by 105